Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

PTC Therapeutics plummets 22% after study in Friedreich Ataxia misses primary endpoint

Published 05/23/2023, 05:47 PM
© Reuters.  PTC Therapeutics plummets 22% after study in Friedreich Ataxia misses primary endpoint
PTCT
-

PTC Therapeutics (NASDAQ:PTCT) shares plunged more than 22% after-hours following topline results from the MOVE-FA trial of vatiquinone in patients with Friedreich ataxia.

According to the report, the study did not meet its primary endpoint of statistically significant change in mFARS score at 72 weeks in the primary analysis population.

While being disappointed that the study did not achieve its primary endpoint, CEO Matthew Klein said they are encouraged by the findings of meaningful impact on several different aspects of FA disease progression and morbidity over 72 weeks.

“Given the signals of clinical benefit, vatiquinone's well-established safety profile in children, and the unmet medical need for pediatric patients with FA, we look forward to discussing a potential path to registration with regulatory authorities,” added Klein.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.